Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program

Histone modifications in cancer can contribute to pathogenesis. Here, the authors demonstrate that targeting epigenetic modifier Ezh2 hinders metastatic behaviour in Luminal B breast cancer models, and highlight a mechanism where Ezh2 contributes to metastatic behaviour by repression of FOXC1.

Guardado en:

Detalles Bibliográficos
Autores principales:	Alison Hirukawa, Harvey W. Smith, Dongmei Zuo, Catherine R. Dufour, Paul Savage, Nicholas Bertos, Radia M. Johnson, Tung Bui, Guillaume Bourque, Mark Basik, Vincent Giguère, Morag Park, William J. Muller
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/08e7c695e7a0496dbcbb93d281626f1b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:08e7c695e7a0496dbcbb93d281626f1b
record_format	dspace
spelling	oai:doaj.org-article:08e7c695e7a0496dbcbb93d281626f1b2021-12-02T17:32:01ZTargeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program10.1038/s41467-018-04864-82041-1723https://doaj.org/article/08e7c695e7a0496dbcbb93d281626f1b2018-06-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-04864-8https://doaj.org/toc/2041-1723Histone modifications in cancer can contribute to pathogenesis. Here, the authors demonstrate that targeting epigenetic modifier Ezh2 hinders metastatic behaviour in Luminal B breast cancer models, and highlight a mechanism where Ezh2 contributes to metastatic behaviour by repression of FOXC1.Alison HirukawaHarvey W. SmithDongmei ZuoCatherine R. DufourPaul SavageNicholas BertosRadia M. JohnsonTung BuiGuillaume BourqueMark BasikVincent GiguèreMorag ParkWilliam J. MullerNature PortfolioarticleScienceQENNature Communications, Vol 9, Iss 1, Pp 1-15 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Alison Hirukawa Harvey W. Smith Dongmei Zuo Catherine R. Dufour Paul Savage Nicholas Bertos Radia M. Johnson Tung Bui Guillaume Bourque Mark Basik Vincent Giguère Morag Park William J. Muller Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program
description	Histone modifications in cancer can contribute to pathogenesis. Here, the authors demonstrate that targeting epigenetic modifier Ezh2 hinders metastatic behaviour in Luminal B breast cancer models, and highlight a mechanism where Ezh2 contributes to metastatic behaviour by repression of FOXC1.
format	article
author	Alison Hirukawa Harvey W. Smith Dongmei Zuo Catherine R. Dufour Paul Savage Nicholas Bertos Radia M. Johnson Tung Bui Guillaume Bourque Mark Basik Vincent Giguère Morag Park William J. Muller
author_facet	Alison Hirukawa Harvey W. Smith Dongmei Zuo Catherine R. Dufour Paul Savage Nicholas Bertos Radia M. Johnson Tung Bui Guillaume Bourque Mark Basik Vincent Giguère Morag Park William J. Muller
author_sort	Alison Hirukawa
title	Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program
title_short	Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program
title_full	Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program
title_fullStr	Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program
title_full_unstemmed	Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program
title_sort	targeting ezh2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/08e7c695e7a0496dbcbb93d281626f1b
work_keys_str_mv	AT alisonhirukawa targetingezh2reactivatesabreastcancersubtypespecificantimetastatictranscriptionalprogram AT harveywsmith targetingezh2reactivatesabreastcancersubtypespecificantimetastatictranscriptionalprogram AT dongmeizuo targetingezh2reactivatesabreastcancersubtypespecificantimetastatictranscriptionalprogram AT catherinerdufour targetingezh2reactivatesabreastcancersubtypespecificantimetastatictranscriptionalprogram AT paulsavage targetingezh2reactivatesabreastcancersubtypespecificantimetastatictranscriptionalprogram AT nicholasbertos targetingezh2reactivatesabreastcancersubtypespecificantimetastatictranscriptionalprogram AT radiamjohnson targetingezh2reactivatesabreastcancersubtypespecificantimetastatictranscriptionalprogram AT tungbui targetingezh2reactivatesabreastcancersubtypespecificantimetastatictranscriptionalprogram AT guillaumebourque targetingezh2reactivatesabreastcancersubtypespecificantimetastatictranscriptionalprogram AT markbasik targetingezh2reactivatesabreastcancersubtypespecificantimetastatictranscriptionalprogram AT vincentgiguere targetingezh2reactivatesabreastcancersubtypespecificantimetastatictranscriptionalprogram AT moragpark targetingezh2reactivatesabreastcancersubtypespecificantimetastatictranscriptionalprogram AT williamjmuller targetingezh2reactivatesabreastcancersubtypespecificantimetastatictranscriptionalprogram
_version_	1718380411078311936

Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program

Ejemplares similares